Core B-Clinical Core
核心 B-临床核心
基本信息
- 批准号:9922101
- 负责人:
- 金额:$ 61.75万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-06-15 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:Alzheimer associated neurodegenerationAlzheimer&aposs DiseaseAmyloidAncillary StudyAsian AmericansAsiansAutopsyBiochemicalBiological MarkersBloodBlood VesselsBrainCaliforniaCardiovascular systemCell LineCerebrospinal FluidCessation of lifeChinese AmericanClinicalClinical DataClinical ResearchClinical TrialsClinical assessmentsCognitiveCollaborationsCollectionConsentDataData SetDementiaDepositionDiagnosticDiseaseEcosystemEducationEnrollmentEthnic OriginFemaleFibroblastsFundingGenerationsGeneticHispanicsHome environmentImageImpaired cognitionIndividualInvestigationLinkLongevityLongitudinal cohortMagnetic Resonance ImagingMethodologyMinorityMissionMolecularNeurocognitiveNeurologicParticipantPeripheral Blood Mononuclear CellPopulationPositron-Emission TomographyProceduresPunch BiopsyQuestionnairesRaceRandomizedRegistriesResearchResearch PersonnelResearch Project GrantsResearch SupportResolutionResourcesRiskRoleSamplingSkinSpinal PunctureSymptomsSystemTelephoneTelephone InterviewsTissue DonationsTrainingTraining and EducationTranslational ResearchUniversitiesclinical trial participantcognitive testingcohortdata managementdementeddisorder riskeducation researchfollow-upgenetic analysisimprovedinclusion criteriainduced pluripotent stem cellinnovationmild cognitive impairmentneuroimaging markernext generationnoveloutreachpre-clinicalprogramsrecruitretention ratestem cellstau Proteinstissue biomarkers
项目摘要
Core B: Clinical Core
Project Summary/Abstract
The UCI ADRC Clinical Core enrolls, characterizes and follows a cohort of individuals who are cognitively
unimpaired, cognitively impaired, or demented, each of whom complete the Uniform Data Set (UDS) consisting
of physical and neurological exams and a battery of neurocognitive assessments. In addition to this UDS,
participants and their study partners complete questionnaires and assessments unique to our ADRC, and
voluntarily contribute a variety of tissue and biomarker assessments, including genetic analyses, volumetric
imaging, cerebrospinal fluid analyses, and donation of fibroblasts for the generation of induced pluripotent stem
cells (iPSC). Overall, 292 of our current 330 active participants have donated fibroblasts or peripheral blood
mononuclear cells (PBMCs), which have been used to generate 192 iPSC lines by our iPSC Core. Most
participants agree to brain donation at autopsy and we have a high rate of successful completion of autopsy
confirmation at death. Our UDS cohort currently includes 330 active participants. Among this cohort, 60% are
female and one third are non-White race or Hispanic ethnicity. Nineteen percent are demented, 18% meet
criteria for Mild Cognitive Impairment (MCI), and a majority (60%) do not meet diagnostic criteria for MCI or
dementia. Our overall retention rates are very high and above the median for the ADRC system. Most UDS
participants have been enrolled in externally funded ancillary studies, ranging from telephone interview studies
to neuroimaging biomarker research. To support the increasing needs of ADRC investigators, including novel
studies of molecular and vascular biomarkers, we will grow this UDS cohort to a steady state n=400, with an
emphasis on enrolling individuals who enable novel studies in support of the UCI ADRC theme “to identify,
quantify, and validate factors that influence the risk of AD across the lifespan.”!
核心B:临床核心
项目总结/摘要
UCI ADRC临床核心招募,表征和跟踪一组认知障碍的个体,
未受损、认知受损或痴呆,每个人都完成了统一数据集(UDS),
身体和神经系统检查以及一系列神经认知评估。除了这个UDS,
参与者和他们的研究伙伴完成我们ADRC独有的问卷和评估,
自愿提供各种组织和生物标志物评估,包括遗传分析、体积分析、
成像、脑脊液分析和用于产生诱导多能干细胞的成纤维细胞捐赠
细胞(iPSC)。总体而言,我们目前的330名积极参与者中有292人捐献了成纤维细胞或外周血
我们使用单个核细胞(PBMC),其已被我们的iPSC Core用于产生192个iPSC系。最
参与者同意在尸检时捐献大脑,我们的尸检成功率很高
确认死亡。我们的UDS队列目前包括330名活跃参与者。在这群人中,60%是
三分之一是非白人或西班牙裔。19%的人精神错乱,18%的人
轻度认知障碍(MCI)的诊断标准,大多数(60%)不符合MCI的诊断标准,
痴呆我们的总体保留率非常高,高于ADRC系统的中位数。大多数UDS
参与者参加了外部资助的辅助研究,
神经影像生物标记物研究。为了支持ADRC调查人员日益增长的需求,包括新的
在分子和血管生物标志物的研究中,我们将使该UDS队列增长至稳态n=400,
强调招募能够支持UCI ADRC主题的新研究的个人,
量化和验证影响整个生命周期中AD风险的因素。"
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
CLAUDIA H. KAWAS其他文献
CLAUDIA H. KAWAS的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('CLAUDIA H. KAWAS', 18)}}的其他基金
LEUKOCYTE-DERIVED BIOMARKERS AS PREDICTORS OF RISK AND PROGRESSION IN ALZHEIMER'
白细胞衍生的生物标志物作为阿尔茨海默病风险和进展的预测因子
- 批准号:
8166929 - 财政年份:2009
- 资助金额:
$ 61.75万 - 项目类别:
LEUKOCYTE-DERIVED BIOMARKERS AS PREDICTORS OF RISK AND PROGRESSION IN ALZHEIMER'
白细胞衍生的生物标志物作为阿尔茨海默病风险和进展的预测因子
- 批准号:
7951079 - 财政年份:2008
- 资助金额:
$ 61.75万 - 项目类别:
Clinical and Pathological Studies in the Oldest Old
最古老的临床和病理学研究
- 批准号:
8230622 - 财政年份:2002
- 资助金额:
$ 61.75万 - 项目类别:
Clinical and Pathological Studies in the Oldest Old
最古老的临床和病理学研究
- 批准号:
7463369 - 财政年份:2002
- 资助金额:
$ 61.75万 - 项目类别:
Clinical and Pathological Studies in the Oldest Old
最古老的临床和病理学研究
- 批准号:
6934497 - 财政年份:2002
- 资助金额:
$ 61.75万 - 项目类别:
Clinical and Pathological Studies in the Oldest Old
最古老的临床和病理学研究
- 批准号:
6907727 - 财政年份:2002
- 资助金额:
$ 61.75万 - 项目类别:
Clinical and Pathological Studies in the Oldest Old
最古老的临床和病理学研究
- 批准号:
7496763 - 财政年份:2002
- 资助金额:
$ 61.75万 - 项目类别:














{{item.name}}会员




